RecruitingPhase 1 / Phase 2NCT03167437
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, MD